RTP Mobile Logo
Submitted by Anonymous on Fri, 01/10/2014 - 12:15

In these audio proceedings from a closed Think Tank meeting held in September 2013, the invited faculty discuss and debate some of the key clinical management issues across a number of common GI cancers as well as promising research strategies in these areas. The roundtable discussion focused on key presentations and papers and actual cases managed in the practices of the faculty where these data sets factored into their decision-making. This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.
 

Listen to audio excerpts

Track 1: Results of the Phase III TRIBE trial of FOLFOXIRI/bevacizumab versus FOLFIRI/bevacizumab as first-line therapy for unresectable metastatic CRC (mCRC)
Track 2: Results of the Phase III AVEX trial: Improvement in survival with bevacizumab/capecitabine versus capecitabine alone for elderly patients with previously untreated mCRC
Track 3: Case discussion: A 30-year-old patient with abdominal pain is found to have a near obstructing sigmoid mass and is diagnosed with KRAS wild-type, BRAF V600e mutation-positive Stage IIIA CRC with liver metastases
Track 4: The developing story of RAS and RAF mutations and next-generation sequencing in CRC
Track 5: Perspectives on first-line therapy for patients with mCRC with and without BRAF mutations
Track 6: Activity and tolerability of neoadjuvant FOLFOX/ziv-aflibercept in a clinical trial
Track 7: Case discussion: A 70-year-old patient with KRAS wild-type CRC with multiple liver and intra-abdominal lymph node metastases achieves a partial response to CAPOX/bevacizumab
Track 8: Second-line therapy options for patients with mCRC
Track 9: Perspectives on the use of ziv-aflibercept versus continuation of bevacizumab after disease progression on FOLFOX/bevacizumab
Track 10: ML18147 (TML): Results of a Phase III trial evaluating continuation of bevacizumab after first disease progression in patients with mCRC
Track 11: North American subgroup results from VELOUR: A Phase III trial of ziv-aflibercept with FOLFIRI as second-line therapy for mCRC
Track 12: Case discussion: A 42-year-old patient with KRAS-mutant mCRC whose disease progresses through multiple lines of bevacizumab-based therapies receives regorafenib
Track 13: Results of a Phase III trial evaluating intravenous calcium/magnesium to prevent oxaliplatin-induced sensory neuropathy
Track 14: Case discussion: A 71-year-old patient with HER2-negative distal gastric adenocarcinoma and peritoneal metastases who experiences disease progression on FOLFOX is enrolled on the REGARD trial
Track 15: REGARD: Results of a Phase III trial of ramucirumab as second-line therapy for metastatic gastric or gastroesophageal junction (GEJ) cancer
Track 16: Current status of RAINBOW: A Phase III trial of weekly paclitaxel with or without ramucirumab for metastatic gastric cancer (mGC)
Track 17: Results of the AVAGAST trial: First-line capecitabine/cisplatin with bevacizumab or placebo for advanced GC
Track 18: Future directions with and ongoing clinical trials evaluating ramucirumab in GC, hepatocellular carcinoma (HCC) and other solid tumors
Track 19: Case discussion: A 57-year-old patient with a moderately differentiated adenocarcinoma of the GEJ receives neoadjuvant chemoradiation therapy
Track 20: Results from the CROSS study: Neoadjuvant chemoradiation therapy for esophageal or GEJ cancer
Track 21: Viewpoints on the use of neoadjuvant anti-HER2-based therapy for HER2-positive GC
Track 22: Use of a modified 5-FU/trastuzumab regimen for patients with mGC who experience oxaliplatin-related thrombocytopenia with FOLFOX/trastuzumab
Track 23: Therapeutic options for patients with metastatic HER2-positive gastric and gastroesophageal cancers
Track 24: TRIO-013/LOGiC: Results of a Phase III trial of lapatinib in combination with capecitabine and oxaliplatin for HER2-positive mGC
Track 25: Trials of T-DM1 and pertuzumab in HER2-positive advanced GC
Track 26: Evaluation of MET pathway biomarkers in a Phase II study of rilotumumab (AMG 102) or placebo with epirubicin, cisplatin and capecitabine for locally advanced or metastatic GC
Track 27: MetGastric: A Phase III trial of onartuzumab (MetMAb) in combination with mFOLFOX6 for patients with metastatic HER2-negative, MET-positive adeno-carcinoma of the stomach or GEJ
Track 28: Differential mechanisms of action of rilotumumab and onartuzumab
Track 29: Targeting the MET pathway in GC
Track 30: Results of the PRODIGE 4/ACCORD 11 trial: Effect on quality of life of FOLFIRINOX compared to gemcitabine in patients with metastatic pancreatic cancer
Track 31: MPACT: Results of a Phase III trial of weekly nanoparticle albumin-bound (nab) paclitaxel with gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas
Track 32: Case discussion: A 71-year-old patient presents with increasing fatigue, weight loss and ankle swelling and is diagnosed with poorly differentiated adenocarcinoma of the pancreas
Track 33: Critical evaluation of therapeutic options for patients with advanced pancreatic cancer
Track 34: Gemcitabine/nab paclitaxel versus FOLFIRINOX for patients with advanced pancreatic cancer
Track 35: Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of HCC
Track 36: Critical assessment of local treatment modalities in HCC
Track 37: Evaluation of sorafenib with chemotherapy for advanced HCC
Track 38: Case discussion: A 58-year-old patient diagnosed with hepatitis C 14 years ago presents with chest pain and is found to have multiple liver lesions consistent with HCC
Track 39: Choosing between liver-directed therapy and systemic therapy for advanced HCC
Track 40: Dosing of sorafenib and incidence of hand-foot syndrome
Track 41: Results of a Phase II trial evaluating the MET inhibitor tivantinib as second-line therapy for advanced HCC
Track 42: METIV-HCC: An ongoing Phase III trial of tivantinib versus placebo as second-line therapy for patients with MET-high inoperable HCC
Track 43: Investigations of novel anti-angiogenic inhibitors — ramucirumab and regorafenib — for patients with HCC and disease progression on sorafenib
Track 44: Case discussion: A 60-year-old patient with multiple liver metastases is diagnosed with a well-differentiated neuroendocrine tumor (NET)
Track 45: Response to octreotide > radioembolization in carcinoid NET
Track 46: Dosing patterns of octreotide for patients with NET
Track 47: Status of SWOG-S0518: An ongoing Phase III trial of octreotide with interferon alpha versus octreotide with bevacizumab for advanced, poor-prognosis carcinoid NET
Track 48: Case discussion: A 52-year-old patient who previously received treatment for a well-differentiated pancreatic NET presents with new hepatic lesions and opts for treatment with everolimus
Track 49: Sequencing of first-line therapeutic options for patients with metastatic pancreatic NET
Track 50: Results of a Phase III trial evaluating failure-free survival for patients with localized GI stromal tumors (GIST) treated with adjuvant imatinib
Track 51: Duration of adjuvant imatinib for GIST
 
FACULTY:
 
Johanna C Bendell, MD
Director, GI Oncology Research
Associate Director
Drug Development Unit
Sarah Cannon Research Institute
Nashville, Tennessee
 
Charles S Fuchs, MD, MPH
Director
Center for Gastrointestinal Cancer
Dana-Farber/Harvard Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
Richard M Goldberg, MD
Professor of Medicine
Physician-in-Chief
OSUCCC-­James Cancer Hospital and Richard J Solove Research Institute
Klotz Family Chair in Cancer Research
The Ohio State University
Columbus, Ohio
 
J Randolph Hecht, MD
Professor of Clinical Medicine
Carol and Saul Rosenzweig Chair in Cancer Therapies Development
Director, UCLA GI Oncology Program
Santa Monica, California
 
Eileen M O’Reilly, MD
Associate Attending
GI Medical Oncology Service
Memorial Sloan-Kettering
Cancer Center
Associate Professor of Medicine
Weill Medical College of
Cornell University
New York, New York
 
Philip A Philip, MD, PhD
Professor of Oncology and Medicine
Director of GI and
Neuroendocrine Tumors
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan
 
MODERATOR:
 
Neil Love, MD
Research To Practice
Miami, Florida